Abstract
Many preclinical and clinical results indicate that liposomal systems can serve as effective adjuvants to subunit vaccines by enabling the formulation and delivery of vaccine antigens and immunopotentiators. The adjuvant effect of liposomes usually depends on both the composition of the lipid vesicles and their physical association with the vaccine antigen. This chapter describes methods for the preparation and characterization of sterile small, mostly unilamellar, lipid vesicles and for their association with vaccine antigens. It gives also some recommendations for the optimization of liposomal vaccines in preclinical testing. The most common immunopotentiators used in liposomal adjuvants are also described.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Pashine, A., Valiante, N. M., Ulmer, J. (2005) Targeting the innate immune response with improved vaccine adjuvants. Nat Med 11, S63–S68.
Guy, B. (2007) The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 5, 505–517.
Alving, C. R. (1991) Liposomes as carriers of antigens and adjuvants. J Immunol Methods 140, 1–13.
Glück, R. (1995) Liposomal presentation of antigens for human vaccines, in (Powell, M. F., Newman, M. J., eds.) Vaccine Design: The Subunit and Adjuvant Approach. Plenum Press, New York, pp 325–343.
Mori, M., Nishida, M., Maekawa, N., Yamamura, H., Tanaka, Y., Kasai, M., Taneichi, M., Uchida, T. (2005) An increased adjuvanticity of liposomes by the inclusion of phosphatidylserine in immunization with surface-coupled liposomal antigen. Int Arch Allergy Immunol 136, 83–89.
Perrin-Cocon, L., Agaugué, S., Coutant, F., Saint-Mezar, P., Guironnet-Paquet, A., Nicolas, J. F., Andre, P., Lotteau, V. (2006) Lysophosphatidylcholine is a natural adjuvant that initiates cellular immune responses. Vaccine 24, 1254–1263.
Lipford, G., Wagner, H., Heeg, K. (1994) Vaccination with immunodominant peptides encapsulated in Quil A-containing liposomes induces peptide-specific primary CD8+ cytotoxic T-cells. Vaccine 12, 73–80.
White, K., Rades, T., Kearns, P., Toth, I., Hook, S. (2006) Immunogenicity of liposomes containing lipid core peptides and the adjuvant Quil A. Pharm Res 23, 1473–1481.
Garcon, N., Chomez, P., Van Mechelen, M. (2007) GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 6, 723–739.
Vandepapeliere, P., Horsmans, Y., Moris, P., Van Mechelen, M., Janssens, M., Koutsoukos, M., Van Belle, P., Clement, F., Hanon, E., Wettendorf, M., Garcon, N., Leroux-Roels, G. (2008) Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 26, 1375–1386.
Evans, J. T., Cluff, C. W., Johnson, D. A., Lacy, M. J., Persing, D. H., Baldridge, J. R. (2003) Enhancement of antigen-specific immunity via the TLR-4 ligands MPL™ adjuvant and Ribi.529. Expert Rev Vaccines 2, 219–229.
Turanek, J., Ledvina, M., Kasna, A., Vacek, A., Hribalova, V., Krejci, J., Miller, A. D. (2006) Liposomal preparations of muramyl glycopeptides as immunomodulators and adjuvants. Vaccine 24, S2/90–S2/91.
Lemaire, G., Tenu, J. P., Petit, J. F., Lederer, E. (1986) Natural and synthetic trehalose diesters as immunomodulators. Med Res Rev 6, 243–274.
Christensen, D., Korsholm, K. S., Rosenkrands, I., Lindenstrom, T., Andersen, P., Agger, E. M. (2007) Cationic liposomes as vaccine adjuvants. Expert Rev Vaccines 6, 785–796.
Heurtault, B., Thomann, J. S., Jedrzejewska, J., Wels, W. S., Schuber, F., Frisch, B. (2006) Liposome-based systems for anti-tumor vaccination: influence of lipopeptide adjuvant. J Liposome Res 16, 205–213.
Patel, G. B., Chen, W. (2005) Archaeosome immunostimulatory vaccine delivery system. Curr Drug Deliv 2, 407–421.
Guy, B., Pascal, N., Francon, A., Bonnin, A., Gimenez, S., Lafay-Vialon, E., Trannoy, E., Haensler, J. (2001) Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine. Vaccine 19, 1794–1805.
Chen, W., Yan, W., Huang, L. (2008) A simple but effective cancer vaccine consisting of an antigen and a cationic lipid. Cancer Immunol Immunother 57, 517–530.
Mayer, L. D., Hope, M. J., Cullis, P. R. (1986) Vesicles of variable sizes produced by a rapid extrusion procedure. Biochem Biophys Acta 858, 161–168.
Mayhew, E., Lazo, R., Vail, W. J., King, J., Green, A. M. (1984) Characterization of liposomes produced using a microemulsifier. Biochim Biophys Acta 775, 169–174.
Batzri, S., Korn, E. D. (1973) Single bilayer liposomes prepared without sonication. Biochim Biophys Acta 298, 1015–1019.
Zadi, B., Gregoriadis, G. (2000) A novel method for high-yield entrapment of solutes into small liposomes. J Liposome Res 10, 73–80.
Schwarz, D., Zirwer, D., Gast, K., Meyer, H. W., Lachmann, U. (1988) Preparation and properties of large octylglucoside dialysis/adsorption liposomes. Biomed Biochim Acta 47, 609–621.
Brown, R. E., Jarvis, K. L., Hyland, K. J. (1989) Protein measurement using bicinchoninic acid: elimination of interfering substances. Anal Biochem 180, 136–139.
Zaks, K., Jordan, M., Guth, A., Sellins, K., Kedl, R., Izzo, A., Bosio, C., Dow, S. (2006) Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol 176, 7335–7345.
Dow, S. W. (2008) Liposome-nucleic acid immunotherapeutics. Expert Opin Drug Deliv 5, 11–24.
Vangasseri, D. P., Cui, Z., Chen, W., Hokey, D. A., Falo, L. D., Jr., Huang, L. (2006) Immunostimulation of dendritic cells by cationic liposomes. Mol Membr Biol 23, 385–395.
Lonez, C., Vandenbranden, M., Ruysschaert, J.-M. (2008) Cationic liposomal lipids: from gene carriers to cell signaling. Prog Lipid Res 47, 340–347.
Brandl, M., Bachmann, D., Drechsler, M., Bauer, K. H. (1993) Liposome preparation using high pressure homogenizers, in (Gregoriadis, G., ed.) Liposome Technology, 2nd edn. CRC Press, Boca Raton, vol I, pp 49–65.
Schneider, T., Sachse, A., Rössling, G., Brandl, M. (1994) Large-scale production of liposomes of defined size by a new continuous high-pressure extrusion device. Drug Dev Ind Pharm 20, 2787–2807.
Wagner, A., Vorauer-Uhl, K., Katinger, H. (2002) Liposomes produced in a pilot scale: production, purification and efficiency aspects. Eur J Pharm Biopharm 54, 213–219.
Lewis, S. J. (1994) (Wade, A., Weller, P. J., eds.) Handbook of Pharmaceutical Excipients, 2nd edn. The Pharmaceutical Press, London.
Altin, J. G., Parish, C. R. (2006) Liposomal vaccines – targeting the delivery of antigen. Methods 40, 39–52.
Weder, H. G., Zumbuehl, O. (1984) The preparation of variably sized homogeneous liposomes for laboratory, clinical and industrial use by controlled detergent dialysis, in (Gregoriadis, G., ed.) Liposome Technology. CRC Press, Boca Raton, vol III, pp 79–106.
Glück, R. (1999) Adjuvant activity of immunopotentiating reconstituted influenza virosomes (IRIVs). Vaccine 17, 1782–1787.
Schmidtgen, M., Brandl, M. (1995) Detection of lipopolysaccharides in phospholipids and liposomes by using the limulus test. J Liposome Res 5, 109–116.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Haensler, J. (2010). Liposomal Adjuvants: Preparation and Formulation with Antigens. In: Davies, G. (eds) Vaccine Adjuvants. Methods in Molecular Biology, vol 626. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-585-9_6
Download citation
DOI: https://doi.org/10.1007/978-1-60761-585-9_6
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60761-584-2
Online ISBN: 978-1-60761-585-9
eBook Packages: Springer Protocols